Moreover, the anti-DKK1 blocking antibody DKN-01 can reduce tumor burden in the PC-3 AR/NE negative xenograft model, and the therapeutic benefit was dependent on the presence of NK cells [153]. Here, DKK1 is linked to neoplasm.